News

News 2017-11-19T23:06:00+00:00

Autolus Announces Pricing of Initial Public Offering

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 22 June 2018 Second public listing of an Arix company, approximately two years after Arix inception Autolus is Arix’s largest holding, accounting for 24.7% of invested and committed capital to date* Arix agrees to invest $7.2 million (£5.5 million)** in IPO to retain a stake of 8.2% in Autolus [...]

June 22nd, 2018|

Update on Autolus proposed initial public offering in the United States

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 8 June 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its largest Group Business holding Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus”) has filed an amended registration statement on Form F-1 with the U.S. [...]

June 8th, 2018|

Lord John Hutton steps down from Board of Directors of Arix Bioscience plc

LONDON, 31 May 2018: Arix Bioscience plc (LSE: ARIX) (“Arix” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Lord Hutton is stepping down from his position as a Non-Executive Director of Arix Bioscience.   Jonathan Peacock, Chairman of Arix Bioscience, said: “It has been a great pleasure to work with Lord Hutton over the last two years. [...]

May 31st, 2018|

Arix Bioscience forms strategic collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to foster new companies in cancer and infectious diseases

Announces formation of LAB591, an academic “BRIDGE” collaboration focused on creating and supporting new companies in oncology and infectious diseases Collaboration combines Arix’s business building expertise with one of the world’s premier cancer research centres and Evotec’s drug discovery expertise Further enhances Arix’s broad deal-sourcing capabilities LONDON, 31 May 2018: Arix Bioscience plc (“Arix”, London Stock Exchange: ARIX) a global healthcare and life science company [...]

May 31st, 2018|

Iterum Therapeutics plc Closes Initial Public Offering

LONDON, 30 May 2018 Arix Bioscience plc (“Arix”, LSE: ARIX) a global healthcare and life science company supporting medical innovation, today notes that its Group Business Iterum Therapeutics plc (“Iterum”, NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, today closed its initial public offering of 6,150,000 of its ordinary shares at an initial offering price to [...]

May 30th, 2018|

Iterum Therapeutics plc Prices Initial Public Offering

LONDON, 25 May 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its Group Business Iterum Therapeutics plc (NASDAQ: ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, has announced the pricing of its initial public offering of 6,150,000 ordinary shares at a price to the public [...]

May 25th, 2018|

Autolus files for proposed initial public offering in the United States

LONDON, 8 May 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that, its largest Group Business holding, Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus”), has filed a registration statement on Form F-1 (“Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) [...]

May 8th, 2018|

Annual Results 2017

LONDON, 23 April 2018: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience”, “Arix” or the “Company”), a global life sciences company supporting medical innovation, today announces its annual results for the year ended 31 December 2017. Highlights within the period Successful IPO on the Main Market of the London Stock Exchange in February 2017, raising £112 million Acquired direct interests in 8 new Arix Group Businesses, bringing the total [...]

April 23rd, 2018|

Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018

LONDON, 5 April 2018: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience") a global healthcare and life science company supporting medical innovation, announces that Joe Anderson, CEO, will present at the H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018, at 11.30 CEST at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. A webcast of the presentation will be accessible live [...]

April 5th, 2018|

Arix Bioscience plc notes Verona Pharma plc report of positive top-line data from Phase 2b Clinical trial of RPL554 for maintenance treatment of COPD

LONDON, 26 March 2018: Arix Bioscience plc (LSE: ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, is pleased to note the positive data reported by one of its Group Businesses, Verona Pharma, from  the Phase 2b Clinical Trial of RPL554  for Maintenance Treatment of COPD. Commenting on the news, Joe Anderson, CEO of Arix Bioscience, said: “We are pleased to note [...]

March 26th, 2018|